Filing Details

Accession Number:
0001104659-21-025271
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-18 16:56:10
Reporting Period:
2021-02-16
Accepted Time:
2021-02-18 16:56:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1720893 Bioxcel Therapeutics Inc. BTAI Pharmaceutical Preparations (2834) 821386754
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1733272 Frank Yocca C/O Bioxcel Therapeutics, Inc.,
555 Long Wharf Drive
New Haven CT 06511
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-02-16 1,300 $55.88 87,097 No 4 S Direct
Common Stock Disposition 2021-02-16 6,805 $56.49 80,292 No 4 S Direct
Common Stock Disposition 2021-02-16 1,137 $57.71 79,155 No 4 S Direct
Common Stock Disposition 2021-02-16 2,886 $58.54 76,269 No 4 S Direct
Common Stock Disposition 2021-02-16 500 $59.46 75,769 No 4 S Direct
Common Stock Disposition 2021-02-16 1,772 $60.43 73,997 No 4 S Direct
Common Stock Disposition 2021-02-16 600 $61.20 73,397 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.78 to $55.99. The reporting person undertakes to provide BioXcel Therapeutics, Inc. (the "Company"), anysecurity holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.00 to $56.96. The reporting person undertakes to provide the Company, any security holder of the Company, orthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.12 to $57.88. The reporting person undertakes to provide the Company, any security holder of the Company, orthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.02 to $58.98. The reporting person undertakes to provide the Company, any security holder of the Company, orthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.02 to $59.62. The reporting person undertakes to provide the Company, any security holder of the Company, orthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.11 to $60.92. The reporting person undertakes to provide the Company, any security holder of the Company, orthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.09 to $61.75. The reporting person undertakes to provide the Company, any security holder of the Company, orthe staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.